Item 8.01. Other Events.

On November 8, 2022, Spero Therapeutics, Inc. issued a press release announcing the closing of its previously announced exclusive license agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited for tebipenem HBr, an investigational drug being developed as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain bacteria. In connection with closing, pursuant to the license agreement and a previously announced stock purchase agreement between the parties, an affiliate of GSK has purchased 7,450,000 shares of the Company's common stock at a purchase price of $1.20805 per share, resulting in gross proceeds to the Company of approximately $9 million. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



99.1      Press Release, dated November 8, 2022

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses